Blood Test for Alzheimer's Risk Identifies Disease Decades Before Symptoms
Plasma p-tau217 accurately detects preclinical Alzheimer's in cognitively normal adults, potentially enabling earlier intervention.
20 articles
Plasma p-tau217 accurately detects preclinical Alzheimer's in cognitively normal adults, potentially enabling earlier intervention.
New study shows plasma pTau217 test reliably identifies Alzheimer's pathology in the brain, even when other dementia types are present.
New p-tau217 blood test forecasts Alzheimer's symptoms within 3-4 years, potentially revolutionizing early intervention strategies.
Brain-derived pTau217 blood test shows superior accuracy for detecting Alzheimer's pathology compared to existing tests.
A Mayo Clinic study reveals the Lumipulse p-tau217/Aฮฒ42 plasma ratio has variable accuracy in detecting Alzheimer's amyloid pathology.
Large study reveals women accumulate toxic tau proteins faster than men, potentially explaining higher Alzheimer's risk.
New research shows tau pathology disrupts neuronal cargo transport before tangles form โ and a kinase inhibitor can reverse it.
A 19-year cohort study maps how amyloid and tau shift in CSF across the full Alzheimer spectrum, pinpointing the optimal intervention window.
A VA-sponsored trial tested whether the blood pressure drug prazosin could remove toxic proteins linked to CTE and Alzheimer's in combat veterans.
New review reveals promising tau-targeting therapies showing cognitive benefits and slowed brain pathology in Alzheimer's trials.
Scientists identify a distinct tau protein pattern that accelerates cognitive decline years before Alzheimer's symptoms appear.
New research reveals how abnormal tau protein accumulation may connect epilepsy onset after age 55 with increased dementia risk.
New research reveals tiny tau aggregates damage brain synapses before visible plaques form, offering early intervention targets.
A Harvard-developed digital seed amplification assay can precisely quantify TDP-43 protein aggregates in CSF, offering a potential diagnostic breakthrough for frontotemporal dementia.
Scientists discover tanycytes help clear toxic tau from the brain. When damaged, these cells may allow Alzheimer's progression.
New research reveals when harmful tau proteins begin accumulating in Down syndrome brains, offering insights into Alzheimer's prevention.
A newly identified molecular chain reaction links tau aggregates to neuronal death, revealing ZBP1 as a promising therapeutic target in Alzheimer's disease.
A neuron-specific proteasome system governs tau pathology, with APOE4 carriers showing heightened vulnerability as this system declines with age.
UCLA scientists discover why some neurons resist Alzheimer's better than others, revealing a natural protein cleanup system that could lead to new treatments.
A new Nature Neuroscience study reveals an unexpected molecular mechanism that initiates tau aggregation, the hallmark of Alzheimer's disease.